March 31, 2014. A careful analysis of the data calls into question the efficacy of Dalvance (Dalbavandin)… statistics indicate Dalbavandin patients are approximately twice as likely to have worse clinical outcomes compared to patients taking the comparison drug, vancomycin.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony to FDA Advisory Committee on REASANZ (Serelaxin) Injection
March 27, 2014. Given the lack of credible evidence that this injected drug is more effective than placebo, we urge you to advise the FDA to NOT approve it at this time, and to require better research as well as subgroup analyses on African Americans and Latinos.
Read More »Letter to Representative Slaughter in Strong Support of H.R. 1150, the Preservation of Antibiotics for Medical Treatment Act
March 21, 2014. As members of the Patient, Consumer, and Public Health Coalition, we strongly support H.R. 1150, the Preservation of Antibiotics for Medical Treatment Act.
Read More »NCHR Testimony to FDA Advisory Committee on Visian Toric Implantable Collamer Lens
March 14, 2014. Myopia and astigmatism are extremely common and we approached today’s meeting with hope that the evidence would be solid so that people could benefit from this device. I’m sure you did too. However, we have 2 substantial concerns.
Read More »Conference – Evidence for New Medical Products: Implications for Patients and Health Policy
June 13, 2014. Better implementation of evidence-based medicine can improve the quality and cost-effectiveness of health care in the U.S. This can be challenging in evaluating newly approved drugs and medical devices.
Read More »